This petition was submitted during the 2019-2024 parliament
Rejected petition Fund three revolutionary Sickle Cell Anemia medicines on the NHS
Three revolutionary Sickle Cell Anemia treatments - ADAKVEO developed by Novartis, OXBRYTA developed by Global Blood Theraputics, and ENDARI developed by Emmaus Medical inc, are widely available and prescribed in the United State of America and the Middle East.
More details
SCD can affect anyone, although it predominantly affects people from African and Caribbean backgrounds.
1 in 76 babies born in the UK carry sickle cell trait.
Approximately 15,000 people in the UK have sickle cell disorder.
Approximately 270 babies with SCD are born in the UK every year.
Children with SCD are at increased risk for stroke, the risk is highest between the ages of 2 and 16.
Episodes of pain may occur in sickle cell disorder and are generally referred to as a crisis
This petition was rejected
Why was this petition rejected?
It’s about something that the UK Government or Parliament is not directly responsible for.
We can't accept your petition because the UK Government and Parliament aren't responsible for the issue you raise.
Guidance on the commissioning of individual medicines by the NHS in England is produced by the National Institute of Health and Care Excellence (NICE).
NICE's appraisal of the use of crizanlizumab (ADAKVEO) to treat sickle cell disease is currently ongoing, and its provisional recommendations are open to public consultation until 17 December. See:
https://www.nice.org.uk/guidance/indevelopment/gid-ta10470
You can find out more about how to get in touch with NICE at:
https://www.nice.org.uk/get-involved/contact-us
We only reject petitions that don’t meet the petition standards.